

SECTION 1: Identification of the substance/mixture and of the company/undertaking

Product identifiers

Product name : Chloroquine phosphate

Product Number 10-2473

Brand Focus Biomolecules

CAS-No. 50-63-5

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses : For Laboratory Research Use Only

Details of the supplier of the safety data sheet 1.3

Company : Focus Biomolecules

> 400 Davis Drive, Suite 600 Plymouth Meeting, PA 19462

Telephone : +1 855-362-8721

E-mail support@focusbiomolecules.com

Emergency telephone number

Emergency Phone # : +1-215-565-5428

SECTION 2: Hazards identification

Classification of the substance or mixture

GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)

Acute toxicity, Oral (Category 4), H302

For the full text of the H-Statements mentioned in this Section, see Section 16.

GHS Label elements, including precautionary statements 2.2

Pictogram

Warning Signal word

Hazard statement(s) H302

Harmful if swallowed.

P270

Precautionary statement(s) P264

Wash skin thoroughly after handling.

P301 + P312Do not eat, drink or smoke when using this product.

IF SWALLOWED: Call a POISON CENTER/doctor if you feel

Chloroquine phosphate Page 1 of 8 unwell.

P330 Rinse mouth.

P501 Dispose of contents/ container to an approved waste disposal plant.

2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none

SECTION 3: Composition/information on ingredients

3.1 Substances

Formula : $C_{18}H_{26}CIN_3 \cdot 2H_3PO_4$

Molecular weight : 515.87 g/mol CAS-No. : 50-63-5 EC-No. : 200-055-2

Component	Classification	Concentration			
Chloroquine bis(phosphate)					
	Acute Tox. 4; H302	<= 100 %			

For the full text of the H-Statements mentioned in this Section, see Section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice

Consult a physician. Show this safety data sheet to the doctor in attendance. Move out of dangerous area.

If inhaled

If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.

In case of skin contact

Wash off with soap and plenty of water. Consult a physician.

In case of eye contact

Flush eyes with water as a precaution.

If swallowed

Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.

4.2 Most important symptoms and effects, both acute and delayed

The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3 Indication of any immediate medical attention and special treatment needed

No data available

Chloroquine phosphate Page 2 of 8

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media

Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

5.2 Special hazards arising from the substance or mixture

Carbon oxides, Nitrogen oxides (NOx), Oxides of phosphorus, Hydrogen chloride gas

5.3 Advice for firefighters

Wear self-contained breathing apparatus for firefighting if necessary.

5.4 Further information

No data available

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Avoid breathing dust.

For personal protection see section 8.

6.2 Environmental precautions

Do not let product enter drains.

6.3 Methods and materials for containment and cleaning up

Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for disposal.

6.4 Reference to other sections

For disposal see section 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Avoid contact with skin and eyes. Avoid formation of dust and aerosols.

Provide appropriate exhaust ventilation at places where dust is formed. Normal measures for preventive fire protection.

For precautions see section 2.2.

7.2 Conditions for safe storage, including any incompatibilities

Keep container tightly closed in a dry and well-ventilated place.

Light sensitive.

Storage class (TRGS 510): 13: Non Combustible Solids

7.3 Specific end use(s)

Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

Chloroquine phosphate Page 3 of 8

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Components with workplace control parameters

Contains no substances with occupational exposure limit values.

8.2 Exposure controls

Appropriate engineering controls

Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of workday.

Personal protective equipment

Eye/face protection

Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).

Skin protection

Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands.

Full contact

Material: Nitrile rubber

Minimum layer thickness: 0.11 mm Break through time: 480 min

Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M)

Splash contact

Material: Nitrile rubber

Minimum layer thickness: 0.11 mm Break through time: 480 min

Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M)

data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test

method: EN374

If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It should not be construed as offering an approval for any specific use scenario.

Body Protection

Complete suit protecting against chemicals, The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.

Respiratory protection

For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator. For higher level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).

Control of environmental exposure

Do not let product enter drains.

Chloroquine phosphate Page 4 of 8

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

a) Appearance Form: solid Colour: white
 b) Odour No data available
 c) Odour Threshold No data available
 d) pH No data available
 e) Melting Melting point/range: 200 °C (392 °F) point/freezing point

No data available

No data available

f) Initial boiling point No data available and boiling range

g) Flash point No data availableh) Evaporation rate No data availablei) Flammability (solid, No data available

gas)j) Upper/lower No data available

flammability or

m) Relative density

explosive limits
k) Vapour pressure No data available
l) Vapour density No data available

n) Water solubility 50 g/l

o) Partition coefficient: No data available n-octanol/water

p) Auto-ignition No data available

temperature
q) Decomposition No data available

r) Viscosity No data available s) Explosive properties No data available

9.2 Other safety information

No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

No data available

Oxidizing properties

10.2 Chemical stability

Stable under recommended storage conditions.

Chloroquine phosphate Page 5 of 8

10.3 Possibility of hazardous reactions

No data available

10.4 Conditions to avoid

Light.

10.5 Incompatible materials

Strong oxidizing agents

10.6 Hazardous decomposition products

Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen oxides (NOx), Oxides of phosphorus, Hydrogen chloride gas

Other decomposition products - No data available

In the event of fire: see section 5

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Acute toxicity

LD50 Oral - Rat - 623 mg/kg Inhalation: No data available Dermal: No data available

Skin corrosion/irritation

No data available

Serious eye damage/eye irritation

No data available

Respiratory or skin sensitisation

No data available

Germ cell mutagenicity

No data available

Rat

Liver

Sister chromatid exchange

Carcinogenicity

IARC: No component of this product present at levels greater than or equal to 0.1% is identified as

probable, possible or confirmed human carcinogen by IARC.

ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a

carcinogen or potential carcinogen by ACGIH.

NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a known

or anticipated carcinogen by NTP.

OSHA: No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of

regulated carcinogens.

Reproductive toxicity

No data available

Specific target organ toxicity - single exposure

No data available

Specific target organ toxicity - repeated exposure

No data available

Chloroquine phosphate Page 6 of 8

Aspiration hazard

No data available

Additional Information

RTECS: VB2450000

May cause permanent eye injury., To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.

Liver - Irregularities - Based on Human Evidence Liver - Irregularities - Based on Human Evidence

SECTION 12: Ecological information

12.1 Toxicity

No data available

Toxicity to daphnia and other aquatic

EC50 - Daphnia magna (Water flea) - 49.52 mg/l - 24 h

invertebrates

12.2 Persistence and degradability

No data available

12.3 Bioaccumulative potential

No data available

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product

Offer surplus and non-recyclable solutions to a licensed disposal company.

Contaminated packaging

Dispose of as unused product.

SECTION 14: Transport information

DOT (US)

Not dangerous goods

IMDG

Not dangerous goods

Chloroquine phosphate Page 7 of 8

SECTION 15: Regulatory information

SARA 302 Components

No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.

SARA 313 Components

This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

SARA 311/312 Hazards

Acute Health Hazard, Chronic Health Hazard

Massachusetts Right To Know Components

No components are subject to the Massachusetts Right to Know Act.

Pennsylvania Right To Know Components

Chloroquine bis(phosphate)	CAS-No.	Revision Date
	50-63-5	

New Jersey Right To Know Components

· e			
Chloroquine bis(phosphate)	CAS-No.	Revision Date	
	50.63.5		

California Prop. 65 Components

This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other reproductive harm.

SECTION 16: Other information

Further information

Copyright 2020 Focus Biomolecules. License granted to make unlimited paper copies for internal use only. The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. Materials are intended for Laboratory Use only and must be used by qualified technicians. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. Focus Biomolecules and its Affiliates shall not be held liable for any damage resulting from handling or from contact with the above product.

Version: 1.0 Revision Date: 03/03/2020

Chloroquine phosphate Page 8 of 8